Navigation Links
Innovative Tissue Array Technology for High-Throughput Screening of Gene,,,Expression


Many different tissue types on a convenient single-slide format

Carolyn Thomas
Stratagene

Stratagenes Complete View tissue array slides offer further refinement of tissue array technology through optimized tissue fixation and processing procedures that preserve tissue morphology, antigenicity of proteins, and nucleic acid reactivity. This innovative product line consists of murine (male and female) survey and validation array slides. The Complete View survey array slides represent major organ systems, consisting of approximately 104 cell types mounted in duplicate. The Complete View validation array slides include 12 representative tissues from the survey arrays and are useful to test staining procedures and reagents. We report our results using Complete View array slides for hematoxylin and eosin staining of murine tissue, immunostaining of murine tropomyosin, and labeling RNA of murine salivary gland. These tests confirm that Complete View tissue array slides ensure reliable screening results in a convenient, high-throughput format.

To achieve an understanding of the cellular function of gene products requires localizing gene expression to specific cells and tissues. This task can be accomplished through the use of tissue arrays, a collection of diverse tissue samples mounted on a single slide. Proven successful in examining both normal1,2 and cancerous tissues,3,4 tissue arrays can be treated as a single histological slide during staining, immunohistochemistry, or in situ hybridization. The single-slide format affords a high-throughput method for precisely identifying the specific tissues and cell types that express a gene of interest.

Single-Slide Whole-Animal Surveys

One particularly useful application of tissue arrays is the whole-animal survey, in which all tis
'"/>

Source:


Page: All 1 2 3 4 5

Related biology technology :

1. Detecting Gastrin-Releasing Peptide Receptor by in situ PCR on Archived Tissue
2. Simple Isolation of RNA from Tissue and Cultured Cells
3. Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer
4. Hands-free Tissue Disruption No Homogenization Needed
5. Recover High Yields of Total Nucleic Acid from Formalin-fixed, Paraffin-embedded (FFPE) Tissue
6. RNase Activity in Mouse Tissue: Classification, Hierarchy, and Methods for Control
7. Stabilizing RNA in Fresh and Frozen Tissues for RNA Isolation
8. Genomic DNA Preparation from RNAlater Preserved Tissues
9. DNA Isolation From 300 to 450 mg Dried or 600 to 1,200 mg Fresh Leaf Tissue
10. DNA Isolation From 50 to 20 mg of Paraffin-Embedded Tissue
11. Genomic DNA Isolation From 510 mg Marine Invertebrate Tissue

Post Your Comments:
(Date:11/5/2009)... Call on Thursday, November 5, 2009 at 4:30 p.m. E...5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceutica...OGXI ) today reported unaudited financial results ...ber 30, 2009 and reviewed the Company,s highlights...g consolidated results reflect the operations of O...
(Date:11/5/2009)...N.Y., Nov. 5 BioSpecific...ceutical company developing first-in-class collage... results for the third quarter ended September 30,...ptember of this year, the FDA,s Arthritis Advisory...2-0, the approval of XIAFLEX(TM) for the treatment...
(Date:11/5/2009)..., Texas, Nov. 5 Wound Ma...ay that it has entered into a Letter of Intent to ...Health Technologies, Inc. (OTC Bulletin Board: VHG...00 in cash and debt, 4,000,000 shares of WNDM and ... on the Veriscrip technology being acquired from V...
(Date:11/5/2009)...alif., Nov. 5 WaferGen B...ing developer of state-of-the-art genetic analysis...Ph.D. has joined the company,s Scientific Advisory...and commercializing novel molecular diagnostics fo...the development of computational biology systems f...
Breaking Biology Technology:OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4
...he Maryland Stem Cell Research,Commission (Commiss... for,new post-doctoral fellowship grants under RFA...applications from pre-doctoral students and post-,...translational research on,all types of human stem ... fellowships will be funded with each,fellowship b...
...Raptor,Pharmaceuticals Corp. ("Raptor" or the "Com... that its clinical development division, Bennu,Pha...al product candidate,EC Cysteamine. Bennu received... developed by clinical scientists at the Universit... way of its acquisition by,merger of Encode Pharma...
... 17 , - New Deal Provides a Further Opportunity f... Oxford Genome Sciences (UK) Ltd "OGeS" announces...oration with Amgen to discover, develop and,commer...ment of cancer.,This new collaboration will enable...human therapeutic antibodies (mAbs) in cancer base...
Other Biology Technology:Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants 2Raptor Pharmaceuticals Acquires Orphan Clinical Program 2Raptor Pharmaceuticals Acquires Orphan Clinical Program 3Raptor Pharmaceuticals Acquires Orphan Clinical Program 4Raptor Pharmaceuticals Acquires Orphan Clinical Program 5Raptor Pharmaceuticals Acquires Orphan Clinical Program 6Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer 2Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer 3
(Date:11/8/2009)...E, Ind. - Researchers at Purdue University have di...e fibers in spinal cord injuries using nano-sphere...ter an accident. , The synthetic "copolymer mice...s in diameter, or roughly 100 times smaller than t...ave been studying how to deliver drugs for cancer ...
(Date:11/6/2009)...stration is now open for the Society of Interventi...logy (IO) Therapies" Webinar, which will provide t...r treatment of liver tumors, kidney tumor ablation...zation of physicians, scientists and allied health...h through pioneering advances in image-guided ther...
(Date:11/6/2009).... 6 Auburn Hills, MI-based Law Enf...nstalling its locker system and patent-pending Bio.... Department of Health and Human Services, Nationa.... The locker system will support the NIH,s entire...ur nation,s medical research agency. The project ...
Breaking Biology News(10 mins):Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3Society of Interventional Radiology hosts oncology therapies Webinar, offers resources 2Blue Cross and Blue Shield of Florida Now Offers More Choices to Floridas Seniors 59742 1Blue Cross and Blue Shield of Florida Now Offers More Choices to Floridas Seniors 59742 2Blue Cross and Blue Shield of Florida Now Offers More Choices to Floridas Seniors 59742 3New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 1New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 2New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 3New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 4New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 5New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 6New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 7New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 8New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 9New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 10New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 11New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 12New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 13New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 14New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 15New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 16New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 17New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 18New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 19New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 20New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 21New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 22Hologic Expands Healthcare Investment in Asia 5563 1Hologic Expands Healthcare Investment in Asia 5563 2Hologic Expands Healthcare Investment in Asia 5563 3
...which trauma and burn patients are most likely to ...wide range of experimental clinical settings ?an i...outinely used in emergency rooms and intensive car...in the Proceedings of the National Academy of Scie...ng the University of Florida, describe how they we...
...iego (UCSD) have found that Lafora disease, an inh...he age of 30, can be caused by mutations in a gene...aforin. These findings are reported in the current...ciences (PNAS). , Lafora disease is characterized ..., followed by an initial seizure in the second dec...
...cancers from Nigeria, Senegal and North America ha...kely to be diagnosed with a more virulent form of ...searchers from the University of Chicago, working ...geria and the University of North Carolina, found ...ferent pattern of gene expression. Tumors from Afr...
Other Biology News:Doctors closer to using gene analysis to help trauma patients 2Doctors closer to using gene analysis to help trauma patients 3UCSD research reveals mechanism involved with type of fatal epilepsy 2Study reveals dramatic difference between breast cancers in US and Africa 2Study reveals dramatic difference between breast cancers in US and Africa 3Study reveals dramatic difference between breast cancers in US and Africa 4
...emium quality siRNAs you need for your gene silenc... online by providing either the 19-21 base target ...siRNA sequences. (Also check out Ambion's Silencer... are already designed for you.) For your convenien...
Custom siRNA, standard purity from Ambion
...e premium quality siRNAs you need for your gene si...ered online by providing either the 19-21 base tar...nse siRNA sequences. (Also check out Ambion's ...iRNAs, which are already designed for you.) For yo...
...emium quality siRNAs you need for your gene silenc... online by providing either the 19-21 base target ...siRNA sequences. (Also check out Ambion's Silencer... are already designed for you.) For your convenien...
Biology Products: